Every Blueprint protocol is N=1. Every Reddit thread on rapamycin, NAD, or a SIBO cure is N=1. Every "it worked for me" is N=1. We take longevity from biohacker to legit — out of anecdote and into evidence: rigorous trials, real endpoints, ill patients, public results.
Substances with no patent moat — curcumin, berberine, rapamycin, low-dose naltrexone, NAC, urolithin A, peptides, food-derived bioactives — can't attract the $300M+ a traditional FDA approval costs, so they stay stuck: sold as supplements with vague claims, or traded as protocols in a gray zone. Nowhere is this worse than in longevity and gut health, where the loudest anecdotes meet the thinnest evidence and a desperate, self-funding audience runs millions of uncontrolled experiments. The trap is trying to monetize the substance — you can't; the value leaks to generic makers and supplement sellers. So we don't. We build the software stack that makes a rigorous repurposing trial radically cheaper and faster, prove it by running our own — starting in the aging gut — and sell the stack and the speed to everyone else. The evidence is the credibility engine; the software is the business. Longevity is the banner; the gut is where we plant the flag first.
Six forces are aligned simultaneously — a configuration that did not exist two years ago and will not persist.
Each layer attacks one cost or time bottleneck in repurposing. Integrated on one data model, they are the product we sell.
We don't pick candidates by anecdote, and we don't lead with the highest-demand category. We lead with the one that most strengthens the brand — because the brand is the moat. The first portfolio is chosen with our founding CSO.
The split is why a trial exists and who funds it, not who operates it. Both run on the same stack; neither ever takes a margin on a substance — the line that keeps the evidence credible.
We are deliberately entering the two fields most synonymous with overclaiming — longevity and the microbiome — which makes rigor our entire differentiation. Non-negotiable from day one:
The company is built by an operator and led in public by a scientist — deliberately. The founder builds and runs it; the scientific and clinical seats carry the credibility, and they are co-equal co-founders, not hires.
Platform, engineering, fundraising, company-building. Scaled a real-time dispatch operation from zero to a dispatch every other second — the same match-route-fulfill pattern that patient recruitment runs on.
An MD-PhD in GI, microbiome, or geroscience who is frustrated by the field's hype. Owns the methodology and picks the beachhead — the rigor-first voice the company is built around.
A clinical-and-regulatory operator who has taken protocols through IRB/IND before. Runs the trials and owns the FDA workflow — because the first year is getting one rigorous trial out the door.
Accumulated evidence and organized patient demand move guidelines, coverage, and policy. Ten years out, N > 1 is field shorthand for rigorous repurposing evidence — the way "Cochrane review" is shorthand for systematic review. This is what public science should have been doing all along, built as a private, accountable, durable institution.